secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023218
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences Q3 net loss $23.1M; CEO retirement, new pipeline programs announced
--------------------------------------------------------------------------------

- Net loss of $23.1M ($0.48 per share) vs $18.8M ($0.41) in Q3 2021.
- Cash and marketable securities $108.7M; projected to fund operations into H1 2024.
- R&D expenses $18.1M, down slightly from $18.5M YoY.
- CEO John McHutchison to retire end of 2022; President Jason Okazaki named successor.
- Phase 1a trial of next-gen core inhibitor ABI-4334 initiated; new HSV-2 and herpesvirus programs introduced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017022023218/0000950170-22-023218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017022023218/asmb-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer